Related Experiment Video
Updated: Jul 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Pleiotropic effects of statins]
Sigrid Mennickent C1, Marisol Bravo D, Carlos Calvo M
1Departamento de Farmacia, Facultad de Farmacia, Universidad de Concepción, Casilla 237, Concepción, Chile. smennick@udec.cl
Insights
Lowering LDL cholesterol with statins significantly reduces coronary heart disease (CHD) risk and mortality. This review explores statin pharmacology and their additional beneficial effects beyond cholesterol reduction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Elevated serum cholesterol, particularly LDL, is a primary driver of coronary heart disease (CHD).
- Numerous studies link high cholesterol levels to increased CHD incidence and atherosclerosis progression.
Purpose of the Study:
- To review the pharmacology of HMG-CoA reductase inhibitors (statins).
- To discuss the pleiotropic (additional) effects of statins beyond cholesterol reduction.
Main Methods:
- Analysis of epidemiologic and clinical trial data on statin efficacy.
- Review of pharmacological mechanisms and clinical outcomes associated with statin use.
Main Results:
- Decreasing LDL-cholesterol concentration with statins reduces CHD incidence, atherosclerosis progression, morbidity, and mortality.
- A 1% reduction in LDL-cholesterol may yield a 1% decrease in CHD incidence.
- Pooled data analysis showed statin treatment for 5.4 years reduced major coronary events by 31% and total mortality by 21%.
Conclusions:
- Statins are effective in managing hypercholesterolemia and reducing cardiovascular events.
- The pleiotropic effects of statins warrant further investigation for comprehensive cardiovascular risk management.
Abstract:
Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reductase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1% reduction in LDL-cholesterol concentration may result in a 1% decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31% and 21% reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects of these drugs.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pleiotropy